Every Form 4 that LENZ Therapeutics, Inc. (LENZ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LENZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LENZ filings page.
LENZ Therapeutics reported an option grant tied to RA Capital–affiliated entities. A stock option for 22,100 shares of common stock was awarded with an exercise price of $6.63 per share and an expiration date of June 15, 2036.
All 22,100 option shares vest on the earlier of June 15, 2027 or the next annual stockholder meeting, subject to Dr. Scheiner continuing as an Outside Director under the company’s policy. Under Dr. Scheiner’s arrangement with RA Capital, any net cash or stock from exercising this option is turned over to RA Capital for the benefit of its funds and account, and the reporting persons disclaim beneficial ownership beyond any pecuniary interest.
LENZ Therapeutics director George Jeffrey P. received a stock option grant covering 22,100 shares of common stock. The option has an exercise price of $6.63 per share and expires on June 15, 2036.
All 22,100 shares vest in a single tranche, provided he continues to serve as an Outside Director, on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders. Following this grant, he holds options for 22,100 shares directly.
LENZ Therapeutics director Kimberlee C. Drapkin received a stock option grant for 22,100 shares of common stock at an exercise price of $6.63 per share. The option expires on June 15, 2036 and represents a compensation-related award, not an open-market purchase or sale.
All 22,100 option shares vest in a single installment, provided she continues to serve as an Outside Director. Vesting occurs on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders. Following this grant, she holds 22,100 options directly.
LENZ Therapeutics director James W. McCollum received a new stock option grant for 22,100 shares of common stock. The option has an exercise price of $6.63 per share and expires on June 15, 2036. Following this grant, he holds options for 22,100 shares directly.
According to the terms, all 22,100 option shares vest in a single tranche if he continues serving as an Outside Director through the vesting date. Vesting occurs on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders.
LENZ Therapeutics, Inc. reported that director Shelley B. Thunen received a grant of stock options for 22,100 shares of common stock at an exercise price of $6.63 per share. These options expire on June 15, 2036 and will vest 100% on June 15, 2027 or the next annual stockholder meeting, provided she continues as an Outside Director.
LENZ Therapeutics director Frederic Guerard received a grant of stock options for 22,100 shares of common stock. The options have an exercise price of $6.63 per share and expire on June 15, 2036. Following this grant, Guerard holds 22,100 derivative securities directly.
According to the vesting terms, all 22,100 options vest 100% on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders, as long as he continues to serve as an Outside Director under the company’s Outside Director Compensation Policy.
LENZ Therapeutics director-related entities received a new stock option award linked to board service. A stock option covering 22,100 shares of common stock was granted with an exercise price of $6.63 per share and an expiration date of June 15, 2036. The option vests 100% on the earlier of June 15, 2027 or the next annual stockholder meeting, provided the reporting person continues as an Outside Director. Under an arrangement with RA Capital Management, L.P., the option is held for the benefit of the RA Capital Healthcare Fund, the RA Capital Nexus Fund II, and a separately managed account, and the reporting person disclaims beneficial ownership because any net proceeds must be turned over to the adviser to offset advisory fees.
LENZ Therapeutics director George Jeffrey P. reported an open-market purchase of common stock. On March 27, 2026, he bought 5,592 shares of LENZ Therapeutics, Inc. at a weighted average price of $8.9217 per share, within a price range of $8.80 to $9.12.
Following this transaction, he directly holds 5,592 shares of LENZ common stock. The filing notes that the total represents multiple individual trades aggregated into the reported weighted average price.
LENZ Therapeutics director and CEO Evert B. Schimmelpennink made an open-market purchase of 28,089 shares of Common Stock. The shares were bought on March 27, 2026 at a weighted average price of $8.9505 per share, within a price range of $8.80 to $9.25. Following this transaction, he directly owns 77,289 shares of LENZ Therapeutics Common Stock.
LENZ Therapeutics, Inc. Chief Financial Officer Daniel R. Chevallard reported an open-market purchase of 7,500 shares of common stock at $8.57 per share. Following this transaction, his direct holdings increased to 12,886 shares of LENZ common stock.
LENZ Therapeutics’ Chief Commercial Officer, Shawn Olsson, reported new equity awards. On January 2, 2026, Olsson received a stock option covering 84,200 shares of LENZ Therapeutics common stock at an exercise price of $16 per share, expiring on January 1, 2036. The option vests over time, with 25% of the shares vesting on the one-year anniversary of January 2, 2026 and the remaining shares vesting monthly thereafter while Olsson continues as a service provider.
On the same date, Olsson was also granted 14,000 restricted stock units, each representing a right to receive one share of common stock. These RSUs vest with 25% of the award vesting on the one-year anniversary of the January 2, 2026 grant date, and the rest vesting in equal installments every six months, subject to continued service.
LENZ Therapeutics, Inc. reported an equity grant to its Chief Medical Officer, Marc Odrich, effective January 2, 2026. He received a stock option for 84,200 shares of common stock with an exercise price of $16 per share, expiring on January 1, 2036. The option vests 25% one year after the January 2, 2026 vesting commencement date, with the remaining shares vesting monthly over three years, contingent on his continued service under the company’s 2024 Equity Incentive Plan.
Odrich also received 14,000 restricted stock units (RSUs), each representing one share of common stock. For this award, 25% of the RSUs vest one year after the January 2, 2026 grant date, with the remaining RSUs vesting in eight equal installments every six months, also subject to continued service. Both the options and RSUs are reported as directly owned following these grants.
LENZ Therapeutics Chief Financial Officer Daniel R. Chevallard received new equity awards. On January 2, 2026, he was granted a stock option for 84,200 shares of LENZ Therapeutics, Inc. common stock at an exercise price of $16 per share, with no cash paid for the option itself.
The filing also reports a grant of 14,000 restricted stock units, each representing one share of common stock. Both the option and RSUs vest over time starting from January 2, 2026, and vesting is conditioned on Mr. Chevallard continuing to serve as a Service Provider under the company’s 2024 Equity Incentive Plan.
LENZ Therapeutics, Inc. (LENZ) reported a Form 4 for its Chief Commercial Officer, who executed an option exercise and related stock sales on 11/17/2025. The officer exercised a stock option to acquire 10,000 shares of common stock at $2.08 per share, then sold 4,212 shares at a weighted average price of $25.7385 and 5,788 shares at a weighted average price of $26.3669. After these transactions, the officer directly held 4,733 shares of common stock and 53,241 stock options. The sales were made under a Rule 10b5-1 trading plan entered into on August 12, 2025, which is a pre-arranged plan intended to structure trading in advance.
LENZ Therapeutics disclosed an insider purchase. A Director bought 10,500 shares of common stock on 11/07/2025 at a weighted-average price of $22.7884. After the transaction, the Director beneficially owns 10,500 shares directly and 620,599 shares indirectly through a trust. The indirect holdings include 95,034 shares transferred to the McCollum Living Trust on June 6, 2024.
LENZ Therapeutics (LENZ) reported an insider purchase by its Chief Financial Officer, Daniel R. Chevallard. On 11/07/2025, he bought common stock in two open‑market transactions coded “P”: 20 shares at $22.71 and 2,178 shares at $22.7561. Following these trades, he directly owns 5,386 shares.
Versant entities reported insider sales of 224,974 shares of LENZ Therapeutics, Inc. (LENZ) on 09/30/2025. The Form 4 shows multiple sales by related reporting persons (including Versant Venture Capital VI, L.P. and affiliated Versant GP and Vantage entities) executed at weighted-average prices in ranges of $45.00–$45.99, $46.00–$46.99, and $47.00–$47.02. Post-transaction beneficial ownership amounts are disclosed for direct and indirect holdings, with several Versant entities retaining substantial positions (for example, 1,133,842 shares reported as directly owned by one entity and 842,162 shares indirectly held by another). The filing is signed by Max Eisenberg for the Versant reporting entities on 10/02/2025. The footnotes explain that reported prices are weighted averages from multiple transactions and identify the chain of general partners that may share voting and investment power over the disclosed holdings.
Versant entities reported multiple sales of LENZ Therapeutics common stock on 09/18/2025. The Form 4 shows a series of dispositions at weighted-average prices of $41.5908 (sales between $41.25 and $42.24) and $43.0038 (sales between $42.25 and $43.24), plus small sales at $43.30.
Reported transactions include direct and indirect sales: for example, 49,479 and 40,907 shares sold directly and 24,370 and 20,148 shares sold indirectly across the two weighted-average-price groups. The filings list 1,224,718; 1,183,811; and related post-transaction beneficial ownership totals for the reporting entities, and note 842,162 shares held indirectly by Versant Vantage II, L.P.